Noveome begins Phase II trial of ST266 to treat allergic conjunctivitis

US-based clinical stage biotherapeutics company Noveome has begun its Phase II clinical trial of ST266 to treat allergic conjunctivitis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news